Theratechnologies Resumes Distribution of EGRIFTA SV After FDA Clearance
February 13, 2025
Montreal Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a leading specialty biopharmaceutical company, proudly announced today that it has resumed the distribution of its flagship product, EGRIFTA SV (tesamorelin for injection). This critical step follows the receipt of correspondence from the U.S. Food and Drug Administration (FDA), granting clearance to release two newly manufactured batches of EGRIFTA SV. The product is now available for immediate shipment to pharmacies within Theratechnologies’ extensive network.
EGRIFTA SV, designed to address the needs of adults with HIV experiencing lipodystrophy, represents a significant advancement in the management of body fat alterations in these patients. The therapy is a refined addition to the company s innovative portfolio, which seeks to redefine healthcare standards and improve patient outcomes.
This resumption marks a pivotal moment for Theratechnologies, aligning with its mission to provide patients with access to essential treatments. The reintroduction of EGRIFTA SV into the market speaks to the company’s commitment to meeting regulatory standards and ensuring that healthcare professionals can continue to trust and rely on their products.
In recent market reports, Theratechnologies Inc. maintained 0.263 million shares outstanding, trading at a current price of $1.63 per share. The relaunch of EGRIFTA SV could potentially influence the company s market standing, as investors and stakeholders respond positively to the resumption of a product with substantial clinical demand and patient reliance.
As Theratechnologies Inc. continues to focus on delivering biopharmaceutical innovations, the timely distribution of EGRIFTA SV asserts its dedication to addressing unmet medical needs in the community and reinforcing its position as a leader in specialty treatments.
Comments